Screener
Zymeworks ZYME Zanidatamab — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Zanidatamab | $2,181 | $1,501 | $2,805 | $2,905 |
| ZW171 | (458) | 3,322 | 691 | 5,549 |
| ZW191 | 3,127 | 2,764 | 6,158 | 4,470 |
| ZW220 | (152) | 327 | (55) | 2,525 |
| ZW251 | 3,205 | 2,340 | 5,112 | 6,291 |
| Expense for other preclinical and research programs | 4,192 | 6,174 | 11,456 | 12,250 |
| Unallocated research and development expenses: | ||||
| Salaries and benefits and stock based compensation | 10,681 | 12,034 | 25,440 | 24,757 |
Item 1. Financial Statements
FAQ
- What is Zymeworks's zanidatamab — R&D?
- Zymeworks (ZYME) reported zanidatamab — R&D of $2.18M in Q2 2026.
- What does zanidatamab — R&D mean?
- This metric represents the total organizational effort and resource allocation dedicated to the advancement of the zanidatamab clinical program. It encompasses the strategic focus on clinical trials, regulatory filings, and scientific development activities specific to this bispecific antibody candidate. Tracking this allows investors to assess the company's commitment to its primary pipeline asset and the progression of its clinical development lifecycle.
Ask your AI about Zymeworks's zanidatamab — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude